The Association of the British Pharmaceutical Industry (ABPI) has entered into a new partnership with the Academic Health Science Network (AHSN) to support biomedical innovations for the National Health Service (NHS).
Under the terms of the five-year agreement, the two partners will work jointly to accelerate the introduction of and use of transformative biomedical innovations to NHS England.
Through the collaboration, ABPI and AHSN will develop a process enabling the members from the two organisations to identify and collaborate on projects that would speed up the spread of the new biomedical developments in the NHS.
ABPI chief executive Mike Thompson said: “As a result of this new partnership, patients will be able to benefit from the innovative medicines and technologies of the future faster and more consistently.”
Thompson added: “The prize for success will be a virtuous circle that delivers benefits for patients and the NHS. There will also be economic benefits to the UK from a thriving life sciences ecosystem.”
The projects supported by the partnership will help to address the new national priority areas of the 15 AHSNs.
The priority areas include economic growth, digital and artificial intelligence, research, genomics and personalised medicine, and diagnostics and medicines optimisation.
AHSN Network chair professor Mike Hannay said: “The establishment of the Innovation Exchange model, commissioned by the Office for Life Sciences, provides a step change opportunity to re-engineer a more effective industry interface.
“This, together with the ABPI partnership, will enable companies to benefit from a consistent offering from whichever AHSN they interact with.
“In turn, the NHS will benefit from better identification of products and services that can benefit patients and the health system, as well as improved signposting to relevant agencies and programmes where not directly provided by AHSNs.”